EVALUATION OF THE EFFICACY OF THE ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC HEART FAILURE AND RENAL DYSFUNCTION.
Iqboljon Mullaboyev TolibovTashkent State Medical UniversityDurdona Shuhratovna AdilovaTashkent State Medical University
Zenodo (CERN European Organization for Nuclear Research)repository2026
ABI
Abstract
Chronic heart failure (CHF) is frequently accompanied by renal dysfunction, forming cardiorenal syndrome and significantly worsening prognosis. Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated superior outcomes compared with conventional renin–angiotensin system blockade; however, data in patients with impaired renal function remain limited. To evaluate the clinical efficacy, cardiac remodeling effects, and renal safety of sacubitril/valsartan in patients with chronic heart failure and renal dysfunction.
Identifiers
Citations and references
Cited by 00 references